Table 4 : Parameters used to estimate the creatinine clearance*,†, ‡.

Group
Items/Normal range 1 2 3 4 5 6 7 8
CTL AAM QT AAM+ QT DM DM+AAM DM+QT DM+AAM+QT
Crsr (mg/dL)(0.2-0.8) 0.6±0.1 1.1±0.1& 0.7±0.1 0.8±0.1& 1.6±0.2& 1.8±0.2&∂ 1.4±0.2&∂ 1.5±0.2&
Vur (mL/24 h) 45±4 90±6§ 54±7 105±6§ 197±7& 171±8&∂ 187±7& 180±9&∂
uh (mL/h) 1.88 3.75 2.25 4.38 8.21 7.13 7.79 7.50
umin,×102 (mL/min) 3.1 6.3 3.8 7.3 13.7 11.9 13.0 12.5
Crur (mg/dL) 33±6 67±6& 68±7& 77±8& 128±7& 131±5& 116±4&∂ 103±3&∂
CCr(mL/min) 1.7±0.1 3.8±0.1& 3.7±0.2& 7.0±0.3& 11.0±0.6& 13.7±0.4&∂ 10.8±0.4&∂ 8.6±0.3&∂

*Measured on urine collected the first day after different treatments.
†Data expressed in mean ± SD (n=8). The superscript symbol "&" in the same row indicate significant difference
from the normal control (p<0.05). The superscript symbol "∂" in the same row indicates significant difference among
the DM-related groups taking the DM rats as the reference. Dose: ip Moriamin 1.6 mL/rat-day. QT ip treated control
(70 mg/kg-day, suspended in PBS).
‡The creatinine clearance is calculated by the equation: Ccr = (Crurmin)/Crpl.

Chen et al.Journal of Diabetes Research and Clinical Metabolism  2014 3:5DOI : 10.7243/2050-0866-3-5